While your journey may look different than others, you can still forge your own path with advocacy, columnist Marisa Zeppieri ...

The U.S. Food and Drug Administration (FDA) has agreed to review an application by Roche seeking approval of obinutuzumab for the treatment of lupus nephritis, a lupus complication marked by kidney ...

The U.S. Food and Drug Administration (FDA) has granted fast track status to ADI-001, Adicet Bio’s CAR T-cell therapy for systemic lupus erythematosus (SLE) that’s resistant to available treatments, ...

As we flip the page to a new year, the pull of hustle culture on social media hasn’t seemed to change. Messages urge us to do more, achieve more, and push harder. But for those of us living with lupus ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to experimental cell therapy SC291 as a potential treatment for hard-to-manage systemic lupus erythematosus (SLE). Fast ...

Treatment with dapirolizumab pegol is better than a placebo at controlling disease activity in people with systemic lupus erythematosus (SLE), according to new results from a Phase 3 clinical trial.

Depression is highly prevalent among people with systemic lupus erythematosus (SLE), but often goes undiagnosed, according to a single center study in Pakistan. People with lupus are at a higher risk ...

The antimalarial agent hydroxychloroquine doesn’t appear to lower the risk of preeclampsia during pregnancy in women with lupus, a study reports. The study, “Hydroxychloroquine in lupus pregnancy and ...

An interesting video is circulating on social media that I’ve seen more times than I can count. While it may be just a colloquial trend used to boost a content creator’s analytics, it still offers an ...

When the protein TLR7, or toll-like receptor 7 — which normally triggers an immune response against viruses and bacteria — instead builds up in immune cells, the immune system may turn against its own ...

The Lupus Foundation of America (LFA) will use a three-year federal grant — worth up to $500,000 per year — to continue efforts to increase the number of Black lupus patients in the U.S. who ...

Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that tested it in adults with moderate to severely active systemic lupus ...